October 26th, Eli Lilly and Co(LLY.US) announces financial results for the third quarter ended September 30, 2021. According to the financial report, Eli Lilly and Co's Q3 revenue in 2021 was $6.773 billion, up 18% from $5.741 billion in the same period last year; net profit was $1.11 billion, compared with $1.208 billion in the same period last year, down 8.11% from a year earlier; gross profit was $5.342 billion, up 21% from a year earlier; earnings per share were $1.22, compared with $1.33 a year earlier.
In the company's revenue, COVID-19 antibody therapy drug revenue of 423.5 million US dollars. By region, revenue in the US market was $3.99 billion, up 26 per cent from a year earlier, while revenue outside the US was $2.783 billion, up 8 per cent from a year earlier.
The company's Q3 total operating expenses (the sum of research and development, marketing, sales and management expenses) was $3.287 billion, an increase of 8 per cent year-on-year. Of this total, the R & D cost was US $1.709 billion, up 17% from the same period last year; the R & D cost of novel coronavirus antibody therapy was about US $50 million; and the marketing, sales and management expenses were US $1.578 billion, up 1% from the same period last year.
Under non-GAAP accounting standards, net profit was $1.764 billion, up 36.85% from $1.289 billion in the same period last year; earnings per share were $1.94, up 37.59% from $1.41 a year earlier; and gross profit margin was $5.351 billion, up 18% from a year earlier.
Looking ahead, the company lowered its earnings per share forecast for 2021 to $6.38-$6.48 and raised its revenue forecast to $272-$27.6 billion, of which revenue related to novel coronavirus antibody rose to $1.3 billion; the gross profit margin forecast remained unchanged at 75%; and R & D costs remained unchanged between $69 and $7.1 billion.
As of press time, Eli Lilly and Co rose 1% before trading to US $247.51.